Le Lézard
Classified in: Health
Subject: FDA

Louisiana Eye Doctor Now Performs PanOptix Lens Placement For Cataract Patients

ALEXANDRIA, La., Sept. 17, 2019 /PRNewswire/ -- Louisiana Eye and Laser, home to ophthalmologists Dr. Michael Redmond and Dr. Patrick Redmond, performed the first PanOptix Lens replacement surgeries in cataract patients in the central and northern Louisiana regions last week. This advanced procedure allows patients to see clearly after surgical cataract removal, discovering more vivid colors and lessening the need for glasses.

A cataract, or clouding of the normally clear lens of the eye, occurs with age, and 9 out of 10 Americans will suffer from cataracts by the age of 65.  Surgery to remove cataracts has been performed for decades. However, patients with lens replacement often complain of fields of blurriness in their vision, or the inability to see either up close or far away.  With the PanOptix lens replacement procedure, patients will be able to see better than ever, many without needing glasses. In the results of a pivotal study at 12 investigational sites in the US, patients demonstrated exceptional, uninterrupted vision, with high patient satisfaction, more than ninety-nine percent of PanOptix patients would choose the same lens again.

LA Eye and Laser invested in this groundbreaking technology to better serve the many patients who trust the doctors and staff at 14 locations across Louisiana.  The first to perform these surgeries are Dr. Michael Redmond and Dr. Patrick Redmond, brothers with a passion for improving people's quality of life through better vision.

"People can still choose the traditional monofocal lens and will appreciate good vision after cataract removal and lens replacement," says Dr. Michael Redmond, "however, that will provide better vision at a distance. The PanOptix Lens enhances a person's ability for near, intermediate, and distance vision." Dr. Patrick Redmond adds: "The PanOptix Lens is the first and only trifocal lens approved by the FDA for U.S. patients undergoing cataract surgery, and we are honored to bring this technology to central Louisiana for our patients."

Louisiana Eye and Laser has 14 locations across Louisiana including Monroe, Alexandria, Ville Platte and others, all providing complete eye care for children, adults, and seniors.  With the PanOptix lens replacement, LA Eye and Laser hopes to provide better vision for people suffering from cataracts.

For more information on Louisiana Eye and Laser, visit www.laeyeandlaser.com and find LA Eye and Laser on Facebook, LinkedIn, and Instagram.

Contact Information

Louisiana Eye and Laser
Michelle Edwards
318-487-2020 ext 1351

SOURCE Louisiana Eye and Laser

These press releases may also interest you

at 16:12
SummaryProducts: Cetrotide 0.25mg Issue: One lot of Cetrotide 0.25mg is being recalled because some vials may have missing stoppers, which could make the product unsterile. What to do: Check the lot number on your product or contact your pharmacist...

at 12:00
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

at 11:00
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

at 10:37
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

at 03:05
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

at 03:05
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...

News published on 18 september 2019 at 16:12 and distributed by: